NEEDHAM, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel's President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024 at 3:00 p.m. ET.
A live webcast of the fireside chat will be available by selecting Events and Presentations under the News & Events tab in the Investors section on candeltx.com. A replay of the webcast will be archived for up to 90 days following the session date.
About Candel Therapeutics
Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically, modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively.
CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic ductal adenocarcinoma (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). The Company recently announced encouraging overall survival data for CAN-2409 in both pancreatic cancer and NSCLC. CAN-2409 received Fast Track Designation from the FDA for prostate cancer, pancreatic cancer, and NSCLC as well as Orphan Drug Designation in pancreatic cancer. Topline data are expected for both the phase 2b (active surveillance population) and the phase 3 (intermediate-to-high-risk prostate cancer) randomized, placebo-controlled clinical trials in localized prostate cancer in Q4 2024.
CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Clinical activity and biomarker data were published in Nature in October 2023. CAN-3110 received Fast Track Designation as well as Orphan Drug Designation from the FDA for recurrent high-grade glioma. The Company expects sharing further clinical updates in the second half of 2024.
Finally, Candel's enLIGHTEN Discovery Platform is a systematic, HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting, the Company presented encouraging data on the first immunotherapy candidate from this platform, Alpha 201-macro-1, which was designed to interfere with the CD47/SIRP1α pathway, in mouse models of breast cancer and lung cancer. During the American Association for Cancer Research (AACR) Annual Meeting in April 2024, the Company presented preclinical data on its immunotherapy candidate for induction of tertiary lymphoid structures (TLS), being developed as a novel therapeutic strategy for solid tumors, its second candidate from the enLIGHTEN Discovery Platform.
For more information about Candel, visit: candeltx.com
Forward-Looking Statements
This press release includes certain disclosures that contain "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including expectations regarding the therapeutic benefit of the Company's programs, the ability of the Company's programs to extend patient survival; and expectations regarding the potential benefits conferred by the Company's inclusion in the broad-market Russell 3000 Index. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; the Company's ability to continue as a going concern; expectations regarding the therapeutics benefit of the Company's programs; that final data from the Company's pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates, and other risks identified in the Company's filings, with the U.S. Securities and Exchange Commission (SEC) including the Company's most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Investor Contact:
Theodore Jenkins
VP, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact:
Kyle Evans
ICR Westwicke
CandelPR@westwicke.com
2024年6月18日、マサチューセッツ州ニードハム(GLOBE NEWSWIRE) - Candel Therapeutics, Inc.(Candel社)(Nasdaq:ナスダック)、がん患者が戦うための多型バイオロジカル免疫療法を開発する臨床段階のバイオ医薬品企業である。CADLPaul Peter Tak, MD, PhD, FMedSci, Candelの社長兼最高経営責任者は、2024年6月25日(火)午後3時に行われるH.C. Wainwright第2回イミューンセルエンゲージャーバーチャルカンファレンスでファイアサイドチャットに参加します。
「News&Events」タブの「Events and Presentations」を選択することで、ファイアサイドチャットのライブウェブキャストを提供します。candeltx.comセッション日から90日間、ウェブキャストのリプレイがアーカイブされます。
Candel Therapeuticsに関する情報
Candelは、個別化された全身性抗腫瘍免疫応答を誘発する、棚からぼた餅の多型バイオロジカル免疫療法を開発することを目的とした臨床段階のバイオ医薬品企業です。
CAN-2409はアデノウイルスプラットフォームからの主力製品候補で、非小細胞肺癌(第2相)、境界性摘出不能膵管癌(第2相)、局所性非転移性前立腺癌(第2相および第3相)で現在臨床試験中です。
CAN-3110はHSVプラットフォームからの主力製品候補で、再発性高度グリオーマ(rHGG)の第1b相臨床試験が現在進行中です。 CAN-3110は、再発性高度グリオーマに対するFDAのファストトラック指定、孤児薬剤指定を受けました。
CandelのenLIGHTEN Discoveryプラットフォームは、固形腫瘍のための新しいウイルス免疫療法を作成するために、人間の生物学と高度な解析を活用したシステマティックでHSVベースの発見プラットフォームです。
「前向きな声明」candeltx.com
出典:Nutex Health, Inc。
このプレスリリースには、修正された1995年の私的訴訟改革法に基づく「前向きな声明」を含むいくつかの開示が含まれています。明示または暗示の声明には、開発プログラムのタイミングおよび進捗状況(企業のプログラムの治療上の利益に関する期待を含む)、企業のプログラムが患者の生存期間を延長する能力、および広範囲なRussell 3000 Indexへの含まれることにより、企業の潜在的な利益が含まれます。 「may、」will、could、would、should、expect、plan、anticipate、intend、believe、estimate、predict、project、potential、continue、target、などの表現は、前向き声明を表すために使われることが意図されていますが、全ての前向き声明がこれらの認識単語を含むわけではありません。本プレスリリースのどの前向き声明も、管理者の現在の期待と信念に基づくものであり、本プレスリリースに含まれるいかなる前向き声明についても、実際のイベントまたは結果が、その前向き声明に含まれるものと異なる可能性のある一連のリスク、不確実性、および重要な要因によって影響を受ける可能性があります。このリスク、不確実性、および重要な要因には、開発プログラムのタイミングおよび進捗状況に関連するもの、企業が持続可能な企業として存続する能力、企業のプログラムの治療的利益を含むが、報告された進行中の研究および試験の仮のデータと最終データが実際には異なる可能性があること、製品候補を効率的に発見および開発する能力、製品候補の規制当局の承認を取得および維持する能力、知的財産を維持する能力、企業のビジネスモデルの実装、および企業のビジネスと製品候補の戦略的計画、および、米国証券取引委員会(SEC)における企業の最新四半期報告書を含む、企業のファイリングで特定された他のリスクが含まれます。企業は、どの前向き声明についても、その前向き声明がなされた日付を基準としてのみ有効であることに注意し、そのような声明のいずれかを公に更新するか、または修正する計画はないと述べます。企業は、そのような声明が基づくイベント、状況、または環境の変化、または実際の結果が前向きな声明に記載された結果と異なる可能性のあるイベント、状況、または環境の変化に対応して、そのような声明に含めないことを決定する場合があります。本プレスリリースに含まれる、いかなる前向き声明も、その日付のみを考慮して、同社の見解を表すものであるとみなすべきであり、その後の日付の同社の見解を表すものであるとは依然保証されていません。」
投資家連絡先:
セオドア・ジェンキンス
シニアバイスプレジデント、投資家関係およびビジネス開発
Candel Therapeutics, Inc.
tjenkins@candeltx.com
メディア連絡先:
カイル・エバンズ
ICR Westwicke
CandelPR@westwicke.com